Small molecule inhibitors of CXCR4
Bikash Debnath1, Shili Xu, Fedora Grande
1Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, School of Pharmacy, 1985 Zonal Avenue, PSC 304, Los Angeles, CA 90089-9121, USA.
Abstract:
CXCR4 is a G-protein-coupled receptor involved in a number of physiological processes in the hematopoietic and immune systems. The SDF-1/CXCR4 axis is significantly associated with several diseases, such as HIV, cancer, WHIM syndrome, rheumatoid arthritis, pulmonary fibrosis and lupus. For example, CXCR4 is one of the major co-receptors for HIV entry into target cells, while in cancer it plays an important role in tumor cell metastasis. Several promising CXCR4 antagonists have been developed to block SDF-1/CXCR4 interactions that are currently under different stages of development. The first in class CXCR4 antagonist, plerixafor, was approved by the FDA in 2008 for the mobilization of hematopoietic stem cells and several other drugs are currently in clinical trials for cancer, HIV, and WHIM syndrome. While the long-term safety data for the first generation CXCR4 antagonists are not yet available, several new compounds are under preclinical development in an attempt to provide safer and more efficient treatment options for HIV and cancer patients.
Insights
The CXCR4 receptor and its SDF-1/CXCR4 axis are implicated in diseases like HIV and cancer. CXCR4 antagonists, such as plerixafor, are being developed for therapeutic applications.
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- CXCR4, a G-protein-coupled receptor, is crucial for hematopoietic and immune system functions.
- The SDF-1/CXCR4 axis is linked to various diseases, including HIV, cancer, WHIM syndrome, rheumatoid arthritis, pulmonary fibrosis, and lupus.
- CXCR4 acts as a co-receptor for HIV entry and promotes cancer metastasis.
Purpose of the Study:
- To review the role of the SDF-1/CXCR4 axis in disease pathogenesis.
- To discuss the development and therapeutic potential of CXCR4 antagonists.
- To highlight ongoing research for safer and more effective treatments.
Main Methods:
- Literature review of studies on CXCR4 and its antagonists.
- Analysis of clinical trial data for approved and investigational drugs.
- Preclinical development of novel CXCR4-targeting compounds.
Main Results:
- Plerixafor, the first CXCR4 antagonist, is FDA-approved for stem cell mobilization.
- Multiple CXCR4 antagonists are in clinical trials for cancer, HIV, and WHIM syndrome.
- New compounds are under preclinical development for improved safety and efficacy.
Conclusions:
- The SDF-1/CXCR4 axis represents a significant therapeutic target for multiple diseases.
- CXCR4 antagonists offer promising treatment strategies for HIV, cancer, and other conditions.
- Continued research is essential to develop next-generation antagonists with enhanced profiles.
